Toggle light / dark theme

Metabolic driver of Parkinson’s disease offers new target for treatment

Researchers have identified a key enzyme driving forms of Parkinson’s disease, and have shown how blocking it restores normal function in animal and cell models, offering a promising new drug target for the condition.

The work is published in the journal Neuron.

In Parkinson’s, a protein known as alpha-synuclein builds up in clumps called Lewy bodies in nerve cells in the brain. These clumps of protein stop these cells from functioning normally, eventually leading the cells to die.

Scientists create rewired brain cells that could cure Alzheimer’s

In a world-first, scientists have figured out how to reprogram cells to fight — and potentially reverse — brain diseases like Alzheimer’s.

Researchers at the University of California, Irvine created lab-grown immune cells that can track down toxic brain buildup and clear it away, restoring memory and brain function in mice.

They did this by turning stem cells — which can become any cell in the body — into brain immune cells called microglia.

A new way to measure uncertainty provides an important step toward confidence in AI model training

It’s obvious when a dog has been poorly trained. It doesn’t respond properly to commands. It pushes boundaries and behaves unpredictably. The same is true with a poorly trained artificial intelligence (AI) model. Only with AI, it’s not always easy to identify what went wrong with the training.

Research scientists globally are working with a variety of AI models that have been trained on experimental and theoretical data. The goal: to predict a material’s properties before taking the time and expense to create and test it. They are using AI to design better medicines and industrial chemicals in a fraction of the time it takes for experimental trial and error.

But how can they trust the answers that AI models provide? It’s not just an academic question. Millions of investment dollars can ride on whether AI model predictions are reliable.

Parvalbumin interneurons regulate rehabilitation-induced functional recovery after stroke and identify a rehabilitation drug

UCLA researchers have made a significant breakthrough in stroke rehabilitation by developing a drug, DDL-920, that replicates the effects of physical therapy in mice. This discovery could pave the way for new treatments that enhance recovery for stroke patients.

Key Findings:

- Understanding Stroke-Induced Brain Disconnection: The study revealed that strokes can disrupt brain connections far from the initial damage site, particularly affecting parvalbumin neurons. These neurons are crucial for generating gamma oscillations—brain rhythms essential for coordinated movements.

- Role of Physical Rehabilitation: Physical therapy was found to restore gamma oscillations and repair connections in parvalbumin neurons, leading to improved motor functions in both mice and human subjects.

/* */